Browse studies

Find your next paid study

64 recruiting studies matching your filters

A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy

This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive…

Chemotherapy-induced Peripheral Neuropathy

Estimated

~$10 – $8,750

Sironax USA, Inc.NCT07765446

Phase 1

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination wi…

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07226986

Phase 3

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thro…

Patients With Chemotherapy-Induced Thrombocytopenia

Estimated

~$10 – $8,750

Jiangsu HengRui Medicine Co., Ltd.NCT07286032

Observational

Effects of Patient Education and Self-Management in Cancer Patients Who Experience Chemotherapy-Induced Taste Alterations

The main questions it aims to answer are: 1. Does completing a standard assessment increase the detection of chemotherapy induced taste changes compared with …

Chemotherapy Side EffectsTaste, Altered

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT06669416

Phase 4

High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy- a Prospective, Double-blind, Randomized, Placebo-controlled Trial

This research study is for participants who are receiving paclitaxel infusion as part of their cancer treatment. The purpose of this study is to test the effec…

Chemotherapy-induced Peripheral NeuropathyCIPN - Chemotherapy-Induced Peripheral Neuropathy

Estimated

~$10 – $6,250

Case Comprehensive Cancer CenterNCT07834281

Phase 2

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): A Randomized, Double-blinded Cross-over Clinical Trial Aimed at Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predic…

Painful Peripheral NeuropathyDiabetic Peripheral Neuropathic Pain (DPN)Chemotherapy Induced Peripheral Neuropathy (CIPN)+1 more

Estimated

~$10 – $6,250

University of RochesterNCT06614322

Phase 2

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/met…

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more

Estimated

~$10 – $7,500

Phase 1

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

Lymphodepleting ChemotherapyMyeloid Malignancies

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06383572

Observational

Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses

Chemotherapy exposure is a serious occupational hazard affecting oncology nurses. Oncology nurses' adherence to chemotherapy handling guidelines is essential t…

Chemotherapy ExposureHandling GuidelinesOncology Nurse+1 more

Estimated

~$10 – $5,625

University of CincinnatiNCT06919653

Phase 2

A Pilot Study of Low-Level Red-Light Therapy Combined With Topical Minoxidil Compared With Topical Minoxidil Alone in Breast Cancer Patients With Chemotherapy-Induced Alopecia

This phase II trial compares the safety and effectiveness of topical minoxidil alone to topical minoxidil in combination with low-level red-light therapy for i…

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07594678

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at …

Neoplasm, ColorectalCognitive ImpairmentCognitive Dysfunction+5 more

Estimated

~$10 – $1,125

Joseph McCollomNCT05014399

Observational

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.

Peripheral Nerve StimulationChemotherapy-induced Peripheral Neuropathy

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06162403